Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis

ABCE 1 Bing Wang
BDE 2 Hongxia Ma
ADG 1 Fengsen Li

Corresponding Author: Fengsen Li, e-mail: li29852721@163.com

Background: Idiopathic pulmonary fibrosis (IPF) is a serious irreversible lung disease. The mechanism of immune checkpoint in idiopathic pulmonary fibrosis is still unknown.

Material/Methods: First, the expression levels of PD-1/PD-L1 on the surface of CD4+ T cells and the proportion of Treg cells in IPF or controls were detected by flow cytometry. Then, expression of TGF-β in blood samples was detected with ELISA. Moreover, a co-culture system was composed of fibroblasts stimulated by TGF-β and CD4+ T cells from healthy people. The proportions of Treg cells and PD-1 in the co-culture system were detected. In addition, we detected the proportion of Treg cells and the level of collagen-1 after adding PD-1 or PD-L1 protein antibody blocker to the co-culture system.

Results: Flow cytometry revealed the upregulated expression of PD-1/PD-L1 in CD4+ T cells of IPF patients. PD-1 appears to inhibit the differentiation of CD4+ T cells into Treg cells. Co-culture of myofibroblasts and CD4+ T cells induced the generation of collagen-1 and reduced the proliferation of CD4+ T cells. When PD-1 was blocked, the inhibition of Treg cell differentiation was reversed, accompanied by decreased collagen-1 production.

Conclusions: This work identified the molecular mechanism of PD-1 in patients with IPF. It may provide a new perspective on the therapeutic effect of PD-1.

MeSH Keywords: Idiopathic Pulmonary Fibrosis • Programmed Cell Death 1 Receptor • T-Lymphocytes • T-Lymphocytes, Regulatory
Background

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial fibrosis pneumonia [1]. The healthy tissue of the lung is replaced by the changed extracellular matrix and the alveolar structure is destroyed, which decreases lung compliance, interrupts gas exchange, and finally leads to respiratory failure and death [2]. IPF affects about 3 million people around the world. With increased age, the incidence of IPF increases dramatically, which causes a huge economic and social burden [3,4]. The disease process of IPF is variable, some of which is unpredictable. Generally, after the diagnosis of symptoms, the time of progression to end-stage respiratory insufficiency and death is about 2–4 years [5].

International consensus guidelines suggested that IPF should be diagnosed at a multidisciplinary level, and known causes of intermittent lung diseases should be excluded by high-resolution computed tomography (HRCT) or surgical lung biopsy [6]. Despite the continuous development of diagnostic criteria, the process is still challenging. Usual interstitial pneumonitis (UIP) is a characteristic histopathological marker of IPF. It includes temporal lobe and spatial heterogeneous fibrosis, fibroblast and myofibroblast clusters, and disordered collagen and extracellular matrix (ECM) over-deposition, leading to the distortion of normal lung structure and the formation of honeycomb cysts [7]. The factors influencing IPF include telomere length, DNA methylation modification, and aging-related changes [8]. In patients with IPF, the pulmonary epithelium becomes dysfunctional. Many chemokines, such as active transforming growth factor-β (TGF-β), play an important regulatory role in this process [9,10].

On the inflammatory level, the level of TGF-β 1 in the lung tissues of patients with IPF is increased [11]. TGF-β 1 is a powerful fibrogenic medium that promotes epithelial cell apoptosis, epithelial mesenchymal transition (EMT), epithelial cell migration, production of other fibrogenic media, circulating fibrocyte recruitment and fibroblast activation, proliferation and transformation into myofibroblasts, and VEGF production [12]. At the cellular immunity level, the effect and mechanism of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) on IPF are not clear. In IPF patients, the proportion of Tregs is lower than in patients with other lung disease or healthy people. The increase of Tregs in peripheral blood is negatively correlated with disease severity [13]. Tregs significantly influence immune tolerance and prevention of autoimmunity, so their quantitative and functional defects may be related to the initial stage of IPF pathogenesis [14]. It had been reported that programmed cell death-1 (PD-1) in CD4+ T cells can promote the development of IPF through production of interleukin-17A (IL-17A) and TGF-β 1 [15]. However, there have been few studies on the relationship between PD-1 and Treg cell decrease in IPF. Some progress has been made in understanding the pathogenesis of IPF and in developing treatment. However, there are still substantial treatment problems. Discovery of a treatment for IPF requires a comprehensive and in-depth understanding of the pathogenesis. The poor prognosis, limited clinical diagnosis and treatment, and high mortality all indicate the need for development of an effective IPF treatment strategy. The aim of this study was to explore the relationship between PD-1 and Treg cells in IPF patients, and to evaluate the effect of PD-1 on myofibroblast functions.

Material and Methods

Cell culture

Human lung fibroblasts (HFL1) from healthy people (Shanghai Zhongqiao Xinzhou, Shanghai, China) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo, Waltham, USA) supplemented with 10% calf serum (GE, Logan, Australia) and 1% antibiotics. Antibiotics (10 000 units/ml penicillin, 10 000 μg/ml streptomycin, and 25 μg/ml amphotericin B) came from GIBCO Life Technologies (Waltham, USA). The fibroblast culture was maintained in 775 (Nest biotechnology, Rahway, USA) and cultured at 37°C in a humid environment containing 5% CO₂. In some of the HFL1 cells, we added 0.05 mg TGF-β (PeproTech, Cranbury, USA) and further cultured them for 12 h. The degree of fibrosis was observed and the subsequent experiments were carried out.

Sorting of CD4+ T cells

First, 5 ml of fresh whole blood of healthy controls was selected, and 5 ml of phosphate-buffered saline (PBS) was added into the whole blood, centrifuged for 10 min at 1200 rpm, and the supernatant was discarded, followed by washing again. A total of 150 μl of magnetic beads was added into the centrifuged precipitate to screen CD4+ T cells (BD, CA, USA), which were then kept in the dark for 30 min. Then, we added 2 ml PBS, blew it with a pipette, placed it on the magnetic frame, and kept it away from light for 10 min. We removed the supernatant from the tube, and did not absorb Brown magnetic beads. Subsequently, we added 1 ml PBS into the supernatant to suspend the magnetic beads, placed them on the magnetic frame, kept them away from light for 10 min, and discarded the supernatant. Finally, the culture medium was added, the magnetic beads were suspended, and we put them into the cell culture bottle for overnight culture. In addition, some cells were co-cultured with myofibroblasts.

Blocking PD-1 pathway in vitro

For the blocking experiment, CD4+ T cells and myofibroblasts were cultured with the method described above, and then
incubated overnight with or without anti-PD-1 (5 μg/ml; eBio-science, Waltham, USA) or PD-Ligand 1 (PD-L1) (2 μg/ml; eBio-science, Waltham, USA) blocking antibody, then continuing for subsequent testing.

**ELISA**

The level of TGF-β in serum was measured using an enzyme-linked immunosorbent assay (ELISA) kit purchased from Abcam (Cambridge, UK). ELISA was performed according to the manufacturer’s protocol to determine the concentration of TGF-β in serum. The supernatant of each sample was diluted in PBS, and 100 μl diluted sample was assessed using the kit. The optical density was measured at a wavelength of 450 nm using a microplate reader. All samples were assessed in triplicate.

**Western blot (WB)**

Protein expression and phosphorylation were detected by WB analysis. The cultured cells were harvested directly in 2×Laemmli buffer in vitro. The protein samples were separated by 10% acrylamide gel and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to their molecular weight. Then, the protein was imprinted on polyvinylidene fluoride (PVDF) membrane at 4°C and 150 mA. After being sealed with 5% skimmed milk powder (Sigma, Vienna, Austria) in PBS-Tween 20, the target protein of the membrane was detected. For PD-1 (Abcam, Cambridge, UK), collagen-1 (Abcam, Cambridge, UK) protein expression was detected. The HD2 and chemiluminescent imagers were used for photography and electrophoresis gel imaging.

**Statistical analysis**

SPSS for Windows V16.0 (Chicago, IL, USA) was used for all analyses. The values are expressed as mean±standard (SD). The chi-square test and t test were used to compare differences between groups. For all experiments, A statistically significant difference was defined as *P* value less than 0.05. Origin 8.0 software (OriginLab, MA, USA) was used to generate the diagram.

**Results**

**PD-1+ CD4+ T cells increased in IPF subjects**

Compared with controls, the expression levels of PD-1 and PD-L1 on the surface of CD4+ T cells in patients with IPF were significantly higher, as shown by flow cytometry (Figure 1A). It is generally believed that TGF-β signaling plays an important role in the development of IPF [17]. Then, we detected TGF-β expression in IPF subjects. Compared with the healthy control group, levels of TGF-β were significantly higher in the IPF group (Figure 1B). These results showed higher expression of both PD-1/PD-L1 and TGF-β in serum of patients with idiopathic pulmonary fibrosis.
The proportion of Treg cells was lower in IPF patients

TGF-β could induce CD4+ T cells to differentiate into Treg by transcription factor Foxp3 [18]. Flow cytometry showed that the proportion of Treg cells in patients with IPF was significantly lower than in controls. However, there was no significant difference in the other immune cell subtypes (Figure 2A). Subsequently, we detected the levels of cytokines in the blood by CBA method. We found that the level of IL-10 was significantly upregulated, as was the level of IL-4 (Figure 2B).

Figure 1. Changes of PD1 pathway and TGF-β in IPF patients. (A) Compared with the controls, the proportion of CD4+ PD1+ and CD4+ PDL1+ cells in IPF patients increased. (B) Compared with the controls, TGF was expressed at significantly higher levels in blood of IPF patients as detected by ELISA. *** P<0.001.
In addition, TGF-β is a cytokine that plays an essential role in induction of fibrosis [19]. Therefore, we added TGF-β to human lung fibroblasts (HLF) to stimulate cell fibrosis and transform them into adult myofibroblasts (Figure 2C). The CD4+ T cells were isolated from healthy human peripheral blood by magnetic beads, and the cell purity was more than 90% (Figure 2D). Two kinds of cells were co-cultured, and the proportion of Treg cells decreased significantly after 24 h (Figure 2E). The results suggested that elevated TGF-β in patients with IPF does not ultimately lead to increased Treg cells.

Figure 2. The effect of cell fibrosis on Treg cells differentiation. (A) Changes of Treg cells proportion in IPF patients was the most obvious. (B) Detection of cytokines in blood of IPF patients. Among them, the changes of IL-4 and IL-10 were the most significant. (C) TGF-beta stimulates pulmonary fibroblasts to obtain myofibroblasts. (TGF-beta concentration: 1 μg/ml) (100×). (D) The purity of CD4+ T cells isolated from peripheral blood by magnetic beads was more than 90%. (E) The proportion of Treg cells decreased significantly after CD4+ T cells co-culture with myofibroblasts for 24 h. ** P<0.01, *** P<0.001.
PD-1 overexpression inhibits differentiation of CD4+ T cells into Treg cells

Compared with myofibroblasts or CD4+ T cells, the expression of PD-1 was increased in the co-culture system (Figure 3A). PD-1 protein antibody blocker was added to the co-culture system and the proportion of Treg cells was assessed 12 h later. It was found that the proportion was significantly increased (Figure 3B). The results showed that PD-1 blocking can reduce the inhibition of Treg cells differentiation. When myofibroblasts were blocked by PD-1, the numbers of Treg cells in the co-culture system increased. Blocking PD1 in CD4+ T cells did not significantly change the proportion of Treg cells. (D) After blocking PDL1 in the myofibroblasts, the numbers of Treg cells in the co-culture system also increased.

Further, we added PD-L1 protein antibody blocker to myofibroblasts for 12 h and then co-cultured them with CD4+ T cells. The results suggest that the inhibition of Treg cell differentiation was also reversed in a few parts (Figure 3D).

PD-1 inhibits myofibroblast proliferation and collagen-1 production in vitro

Then, we evaluated the collagen-1 produced by co-culture of myofibroblasts and CD4+ T cells. We first observed a slight decrease compared with the single myofibroblasts, but, compared with the single CD4+ T cells, the proliferation ratio of co-cultured cells decreased significantly (Figure 4A). Western blot analysis showed that the level of collagen-1 in supernatant of the co-culture system was significantly higher than
that of single myofibroblasts or CD4+ T cells (Figure 4B). In the co-culture system of myofibroblasts blocked by PD-1, the level of collagen-1 decreased significantly. It is worth noting that there was no significant difference in the level of collagen-1 compared with CD4+ T cells. Compared with myofibroblasts alone, the level of collagen-1 was reduced (Figure 4C).

Discussion

IPF is one of the most common and severe forms of induced interstitial lung disease (ILD). Cancer is also a major complication of the disease. Although there have been many approved drugs and other interventions, IPF still is the most challenging interstitial lung disease in clinical treatment [20]. As we all know, PD-1 has become a new biomarker in ILD, and its antibody therapy has been widely used in ILD [21–23]. However, there have been few studies on the mechanism and therapeutic value of PD-1 in IPF. In the present study, molecular detection was used to explore the regulatory effect of PD-1 in IPF on Treg cells. Mechanistically, inhibition of the PD-1 pathway can reverse the Treg cells differentiation, then reduce the generation of collagen-1.

In fact, experimental evidence and histological analysis indicated the presence of innate and adaptive immune cells, especially lymphocytes, which may contribute to alveolar destruction and progressive lung remodeling [24]. The regulation of T cell function was coordinated through co-stimulation and co-inhibition. Inhibitory receptors, including PD-1, have a negative effect on CD4+ T cell function [25]. Blocking the PD-1 pathway can restore T cell function in granulomatous diseases, such as chronic beryllium disease (CBD) and granulomatous disease in polyangiitis (GPA) [26,27]. Blocking the PD-1 pathway can also improve the clinical symptoms of lung cancer [28]. However, the effect of PD-1 on Treg cells in IPF patients has not been previously described. In our results, the PD-1 was highly expressed in IPF patients, accompanied by a decrease in the proportion of Treg cells and an increase in TGF-β content. It has been noted that the increase of TGF-β can promote CD4+ T cells differentiating into Treg cells to some extent [29]. However, the increased TGF-β in the results of this study did not result in increased Treg cells, while Treg cells have plasticity, allowing them to differentiate into Th17 cells under the condition of increased IL-6/PSTAT3 expression [30]. Remarkably, the high level of PD-1/PD-L1 expression resulted in the intrinsic damage of Treg function and the reduction of reactivity of effector clone, which ultimately failed to control HIV infection [31]. However, some studies showed that Treg...
infiltration was significantly related to the infiltration of PD1-positive cells, and it was reported that 81% of tumor patients with PD1-positive lymphocyte infiltration were also in the high Treg subgroup [32]. In the present study, smoking history was significantly different between IPF patients and controls, and smoking seems to be the most relevant risk factor for IPF [33]. However, there are no studies that have found whether smoking affects the expression of PD1/PD-L1 in IPF patients, which needs further exploration.

It is difficult to characterize the phenotype of T cells of IPF. A few studies have demonstrated that T cells in peripheral blood of IPF have specific gene expression characteristics. Based on previous research reports, flow cytometric analysis of explained lung cell suspensions showed the increase of CD8+ cd28null T cells in IPF relative to normal lung explants [34]. Compared with the controls, IPF patients had a higher proportion of lung CD4+ T cells, a higher proportion of CCR4+ CD4+ T cells, and a lower proportion of CCR6+ CD4+ T cells [35]. The present study was different from previous reports, which found that the increased proportion of activated Treg cells was related to the severity of idiopathic pulmonary fibrosis [13]. However, our work showed that the proportion of Treg cells in IPF patients or myofibroblasts decreased significantly, which was related to PD-1/PD-L1 signaling. The decrease numbers of Treg cells may be related to the smoking characteristics of IPF patients, which needs further research [36].

The limitation of this study is that other immunological and non-immunological pathogenic factors of IPF were not examined. For example, lung CCR2+ CD4+ T cells are immunomodulatory and attenuate the development of pulmonary fibrosis [37].

Another issue we did not explore is how TGF-β and the tissue microenvironment cooperate to promote the multiple effects of regulating cell responses of different cell types in IPF [19]. Mesenchymal stem cells can make TGF-β1 downstream signal transduction sensitive, thus regulating IL-6/STAT3 activation, stimulating Treg expansion, and promoting anti-fibrosis [38].

Despite years of intense research, the exact causes of IPF remain unknown. The results of the present study show that PD-1 overexpression inhibits CD4+ T cells differentiating into Treg cells, leading to increased collagen-1 production. Our exploration of the effect of PD-1 in IPF may help discover effect targets.

Conclusions

The levels of PD-1, PD-L1, and TGF-β in IPF patients were increased. The increased PD-1/PD-L further inhibited the differentiation of CD4+ T cells into Treg cells, which can reverse the effect of TGF-β on the differentiation of Treg cells. PD-1 also decreased the proliferation of myofibroblasts co-cultured with CD4+ T cells, but promoted the generation of collagen-1 in myofibroblasts.

Acknowledgements

All authors would like to thank Xiaoting Li for providing the data analysis.

Conflicts of interest

None.

References:

1. Xaubet A, Ancochea J, Molina-Molina M: Idiopathic pulmonary fibrosis. Med Clin (Barc), 2017; 148(4): 170-75
2. Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet, 2017; 389(10082): 1941-52
3. Martinez FJ, Collard HR, Pardo A et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers, 2017; 3: 17074
4. Barratt SL, Creamer A, Hayton C, Chaudhuri N: Idiopathic pulmonary fibrosis (IPF): An overview. J Clin Med, 2018; 7(8): 201
5. Ley B, Collard HR, King TE Jr.: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2011; 183(4): 431-40
6. Raghu G, Collard HR, Egan J Jr et al: An official ATS/ERS/ERS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011; 183(6): 788-824
7. Rabeyrin M, Thivolet F, Ferretti GR et al: Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations. Ann Diagn Pathol, 2015; 19(4): 269-76
8. Sgalla G, Iovene B, Calvello M et al: Idiopathic pulmonary fibrosis: Pathogenesis and management. Respir Res, 2018; 19(1): 32
9. Betensley A, Sharif R, Karamichos D: A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. J Clin Med, 2016; 6(1): 2
10. King TE Jr., Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet, 2011; 378(9807): 1949-61
11. Wolters PJ, Collard HR, Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol, 2014; 9: 157-79
12. Grimminger F, Gunther A, Vancheri C: The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J, 2015; 45(5): 1426-33
13. Hou Z, Ye Q, Qiu M et al: Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis. Respir Res, 2017; 18(1): 170
14. Kotsianidis I, Nakou E, Bouchliou I et al: Global impairment of CD4+CD25+Foxp3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2009; 179(12): 1121–30
15. Celada LI, Kropski JA, Herazo-Maya JD et al: PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. Sci Transl Med, 2018; 10(460): eaar8356
16. American Thoracic Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 2000; 161(2 Pt 1): 646-64
17. Oruqaj G, Kamali S, Vijayan V et al: Compromised pereoxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-beta signaling. Proc Natl Acad Sci USA, 2015; 112(16): E2048–57
18. Liu Y, Zhang P, Li J, Kulkarni AB et al: A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol, 2008; 9(6): 632–40
19. Caja L, Dituri F, Mancarella S et al: TGF-beta and the tissue microenvironment: Relevance in fibrosis and cancer. Int J Mol Sci, 2018; 19(5): 1294
20. du Bois RM: Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov, 2010; 9(2): 129–40
21. Shibaki R, Murakami S, Matsumoto Y et al: Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Med Oncol, 2019; 36(6): 49
22. Uchida T, Kaira K, Yamaguchi O et al: Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer, 2019; 10(4): 975–79
23. Duchemann B, Didier M, Pailler MC et al: [Can nivolumab be used safely in idiopathic pulmonary fibrosis?] Rev Mal Respir, 2019; 36(2): 209–13 [in French]
24. Todd NW, Scheraga RG, Galvin JR et al: Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res, 2013; 6: 63–70
25. Butte MJ, Keir ME, Phamduy TB et al: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 2007; 27(1): 111–22
26. Palmer BE, Mack DG, Martin AK et al: Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J Immunol, 2008; 180(4): 2704–12
27. Wilde B, Hua F, Dolf S et al: Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford), 2012; 51(7): 1188–97
28. Topalian SL, Hodi FS, Brahmer JR et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012; 366(26): 2443–54
29. Haribhai D, Luo X, Chen J et al: TGF-beta1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Adv, 2016; 1(2): 139–51
30. O’Shea JJ, Paul WE: Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science, 2010; 327(5969): 1098–102
31. Nikolova M, Wiedemann A, Muhtarova M et al: Subset- and antigen-specific effects of Treg on CD8+ T cell responses in chronic HIV infection. PLoS Pathog, 2016; 12(11): e1005995
32. Kang MJ, Kim KM, Bae JS et al: Tumor-infiltrating PD1-positive lymphocytes and Foxp3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol, 2013; 6(3): 282–89
33. Zhou LL, Wang M, Liu F et al: Cigarette smoking aggravates bleomycin-induced experimental pulmonary fibrosis. Toxicol Lett, 2019; 303: 1–8
34. Habel DM, Espindola MS, Kitson C et al: Characterization of CD28(null) T cells in idiopathic pulmonary fibrosis. Mucosal Immunol, 2019; 12(1): 212–22
35. Adegunsoye A, Hrusch CL, Bonham CA et al: Skewed lung CCR4 to CCR6 CD4(+) T cell ratio in idiopathic pulmonary fibrosis is associated with pulmonary function. Front Immunol, 2016; 7: 516
36. Jing W, Wang W, Liu Q: Passive smoking induces pediatric asthma by affecting the balance of Treg/Th17 cells. Pediatr Res, 2019; 85(4): 469–76
37. Kawamura K: [Treatment of circulatory diseases: Recent progress. 4. Cardiomyopathies.] Nihon Naika Gakkai Zasshi, 1986; 75(7): 873–80 [in Japanese]
38. Liu M, Zeng X, Wang J et al: Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther, 2016; 7(1): 63